Vanda Pharmaceuticals (VNDA)
Develops and commercializes specialty therapies across psychiatric, sleep, MS, and motion-sickness markets.
$5.24
After hours+0.03 (+0.59%)
At close$5.21(+1.07%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 83.07% | 50.23M shares | |
|---|---|---|---|
| 177 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 9.05% | 5.47M shares | |
| 14 holders · as of Jun 8, 2026 | |||
| Other | ≈ 7.88% | 4.76M shares | |
| remainder | |||
60.46M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
177 holders · 50.23M shares · 30 new positions · 97 increased · 56 reduced · 27 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.65M | 12.66% | +377.7K | Aug 7, 2026 |
| State Street Corp | 3.52M | 5.82% | +500.8K | Aug 7, 2026 |
| AQR Capital Management LLC | 3.50M | 5.78% | +1.89M | Aug 14, 2026 |
| Renaissance Technologies LLC | 3.44M | 5.69% | −318.2K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 2.52M | 4.17% | +42.5K | Aug 13, 2026 |
| Aigh Capital Management LLC | 2.04M | 3.38% | −705.8K | Aug 7, 2026 |
| Acadian Asset Management LLC | 1.92M | 3.17% | +122.5K | Aug 13, 2026 |
| Dimensional Fund Advisors LP | 1.73M | 2.86% | −44.2K | Aug 11, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 8.10% | 4.70M | 13G | Feb 7, 2025 |
| AQR Capital Management, LLC | 5.82% | 3.50M | 13G | Aug 13, 2026 |
| Millennium Management LLC | 5.60% | 3.38M | 13G | Aug 19, 2026 |
| State Street Corporation | 5.10% | 3.02M | 13G | May 12, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 2, 2026 | Gunther Birznieksofficer: SVP, Business Development | Sale | 42,431 | $8.27 | 494,197 |
| Mar 2, 2026 | Mihael Hristos Polymeropoulosdirector, officer, other: President and CEO | Sale | 156,235 | $8.17 | 2,704,496 |
| Mar 2, 2026 | Joakim Wijkstromofficer: SVP, Chief Marketing Officer | Sale | 30,800 | $8.27 | 333,469 |
| Mar 2, 2026 | Kevin Patrick Moranofficer: SVP, CFO & Treasurer | Sale | 42,442 | $8.27 | 411,380 |
| Mar 2, 2026 | Timothy Williamsofficer: SVP & General Counsel | Sale | 42,434 | $8.27 | 377,450 |
| Feb 23, 2026 | Tage Honoredirector | Sale | 30,000 | $8.03 | 93,469 |
House and Senate disclosures
Not reported.